Mission Statement
Reneo is initially developing mavodelpar (REN001) in two rare genetic diseases that typically present with myopathy: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
On the web
Website: https://reneopharma.com/